These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21859946)

  • 41. Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague.
    Agar SL; Sha J; Baze WB; Erova TE; Foltz SM; Suarez G; Wang S; Chopra AK
    Microbiology (Reading); 2009 Oct; 155(Pt 10):3247-3259. PubMed ID: 19589835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic Therapy of Plague: A Review.
    Sebbane F; Lemaître N
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.
    Xiao X; Zhu Z; Dankmeyer JL; Wormald MM; Fast RL; Worsham PL; Cote CK; Amemiya K; Dimitrov DS
    PLoS One; 2010 Oct; 5(10):e13047. PubMed ID: 20976274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].
    Zauberman A; Flashner Y; Levy Y; Vagima Y; Tidhar A; Cohen O; Bar-Haim E; Gur D; Aftalion M; Halperin G; Shafferman A; Mamroud E
    PLoS One; 2013; 8(12):e83560. PubMed ID: 24358292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report.
    Andrianaivoarimanana V; Bertherat E; Rajaonarison R; Rakotondramaro T; Rogier C; Rajerison M
    BMC Pulm Med; 2018 May; 18(1):92. PubMed ID: 29843675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plague Gives Surprises in the Second Decade of the Twenty-First Century.
    Butler T
    Am J Trop Med Hyg; 2023 Nov; 109(5):985-988. PubMed ID: 37748767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice.
    Davis KJ; Vogel P; Fritz DL; Steele KE; Pitt ML; Welkos SL; Friedlander AM; Byrne WR
    Arch Pathol Lab Med; 1997 Aug; 121(8):865-8. PubMed ID: 9278616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Yersinia pestis and the plague.
    Rollins SE; Rollins SM; Ryan ET
    Am J Clin Pathol; 2003 Jun; 119 Suppl():S78-85. PubMed ID: 12951845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks.
    Sha J; Endsley JJ; Kirtley ML; Foltz SM; Huante MB; Erova TE; Kozlova EV; Popov VL; Yeager LA; Zudina IV; Motin VL; Peterson JW; DeBord KL; Chopra AK
    J Clin Microbiol; 2011 May; 49(5):1708-15. PubMed ID: 21367990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a PCR-lateral flow assay for rapid detection of Yersinia pestis, the causative agent of plague.
    Singh R; Pal V; Kumar M; Tripathi NK; Goel AK
    Acta Trop; 2021 Aug; 220():105958. PubMed ID: 34004173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
    Hammerschlag MR; Sharma R
    Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protection Elicited by Attenuated Live
    Cote CK; Biryukov SS; Klimko CP; Shoe JL; Hunter M; Rosario-Acevedo R; Fetterer DP; Moody KL; Meyer JR; Rill NO; Dankmeyer JL; Worsham PL; Bozue JA; Welkos SL
    Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33669472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
    Russell P; Eley SM; Bell DL; Manchee RJ; Titball RW
    J Antimicrob Chemother; 1996 Apr; 37(4):769-74. PubMed ID: 8722542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
    Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
    Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the phoPQ operon in the pathogenesis of the fully virulent CO92 strain of Yersinia pestis and the IP32953 strain of Yersinia pseudotuberculosis.
    Bozue J; Mou S; Moody KL; Cote CK; Trevino S; Fritz D; Worsham P
    Microb Pathog; 2011 Jun; 50(6):314-21. PubMed ID: 21320584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of New Virulence Factors and Vaccine Candidates for
    Andersson JA; Sha J; Erova TE; Fitts EC; Ponnusamy D; Kozlova EV; Kirtley ML; Chopra AK
    Front Cell Infect Microbiol; 2017; 7():448. PubMed ID: 29090192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model.
    Olson RM; Anderson DM
    PLoS One; 2019; 14(5):e0217440. PubMed ID: 31121001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
    Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
    Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Crystal structure of UDP-glucose pyrophosphorylase from Yersinia pestis, a potential therapeutic target against plague.
    Gibbs ME; Lountos GT; Gumpena R; Waugh DS
    Acta Crystallogr F Struct Biol Commun; 2019 Sep; 75(Pt 9):608-615. PubMed ID: 31475928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague.
    Welkos S; Pitt ML; Martinez M; Friedlander A; Vogel P; Tammariello R
    Vaccine; 2002 May; 20(17-18):2206-14. PubMed ID: 12009274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.